Back to top
more

Amicus Therapeutics (FOLD)

(Delayed Data from NSDQ)

$9.36 USD

9.36
1,633,693

-0.22 (-2.30%)

Updated May 29, 2024 04:00 PM ET

After-Market: $9.37 +0.01 (0.11%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for FOLD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Amicus Therapeutics, Inc. [FOLD]

Reports for Purchase

Showing records 121 - 140 ( 171 total )

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 121

03/08/2019

Company Report

Pages: 8

Price: 24.95

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 122

02/04/2019

Company Report

Pages: 8

Price: 24.95

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 123

01/28/2019

Company Report

Pages: 8

Price: 24.95

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 124

01/23/2019

Company Report

Pages: 8

Price: 24.95

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 125

01/21/2019

Company Report

Pages: 8

Price: 24.95

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 126

11/21/2013

Company Report

Pages: 6

Amicus announces revised Fabry agreement and Callidus Biopharma acquisition - Dropping Coverage

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 127

09/30/2013

Industry Report

Pages: 14

Biotechnology/Biopharmaceuticals/BioDefense - KOL Dinner with Dr. Craig McDonald, Oct 2 - Looking Ahead to World Muscle

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 50.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 128

08/08/2013

Company Report

Pages: 5

Q2:13 EPS, Twelve-Month Migalastat Data Coming in Q4:13, Reiterate Underperform

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 129

06/17/2013

Company Report

Pages: 4

Current Migalastat Monotherapy Data Not Adequate for NDA Filing, Reiterate UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 130

05/10/2013

Company Report

Pages: 6

Q1:1 Financial Results

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 131

05/03/2013

Industry Report

Pages: 5

LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 132

03/13/2013

Company Report

Pages: 6

Q4:12 EPS; $52-58M FY:13 Burn Guidance and 12-Month Migalastat Data Pushed to Q3:13 from Q2:13, Reiterate UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 133

03/11/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 134

02/19/2013

Daily Note

Pages: 4

Updated Phase III Migalastat Data Remains Underwhelming, Reiterate UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 135

12/20/2012

Company Report

Pages: 5

Downgrades To Hold & Cuts PT To $3

Provider: CAPSTONE INVESTMENTS

Analyst: GANDHI M

Price: 10.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 136

12/20/2012

Company Report

Pages: 6

Downgrading to UNDERPERFORM from NEUTRAL, Fabry Phase III Study Fails, Lowering Price Target to $1.50

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 137

11/06/2012

Company Report

Pages: 5

Reits Buy : Facets to unfold inDecember.

Provider: CAPSTONE INVESTMENTS

Analyst: GANDHI M

Price: 10.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 138

11/06/2012

Company Report

Pages: 5

Q3:12 EPS, Key Results for Migalastat Monotherapy Coming Q4:12, Reiterate NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 139

10/31/2012

Company Report

Pages: 18

We are initiating coverage with Buy rating and $7 price target

Provider: CAPSTONE INVESTMENTS

Analyst: GANDHI M

Price: 50.00

Research Provided by a Third Party

Company: Amicus Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 140

09/10/2012

Industry Report

Pages: 44

September 2012 Potential Catalysts & Milestones - Monthly Update

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party